- Report
- May 2021
- 70 Pages
United States
From €763EUR$850USD£656GBP
- Report
- January 2024
- 150 Pages
Global
From €4352EUR$4,850USD£3,746GBP
- Report
- August 2022
- 175 Pages
Global
From €8524EUR$9,500USD£7,337GBP
- Report
- October 2023
- 160 Pages
Global
From €3229EUR$3,599USD£2,779GBP
- Report
- February 2024
- 126 Pages
Global
From €4262EUR$4,750USD£3,668GBP
- Report
- February 2023
- 79 Pages
Middle East, Africa
From €1346EUR$1,500USD£1,158GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €449EUR$500USD£386GBP
Jublia is a brand of antifungal medication used to treat fungal infections of the toenails. It is a topical solution that is applied directly to the affected area. The active ingredient in Jublia is efinaconazole, which is a triazole antifungal. It works by inhibiting the growth of the fungus and preventing it from spreading. Jublia is used to treat onychomycosis, which is a fungal infection of the toenails. It is also used to prevent the recurrence of the infection.
Jublia is part of the larger market of infectious diseases drugs, which are medications used to treat a variety of infections caused by bacteria, viruses, fungi, and parasites. These drugs are used to treat a wide range of conditions, from the common cold to more serious illnesses such as HIV/AIDS and malaria.
Some companies in the Jublia market include Novartis, Merck, Pfizer, and GlaxoSmithKline. These companies are all major players in the pharmaceutical industry and have a wide range of products in the infectious diseases drugs market. Show Less Read more